Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
China Obesity Approval Puts Pfizer’s GLP 1 Bet In Sharper Focus
Pfizer has received approval from China for its GLP-1 obesity therapy, Xianweiying (ecnoglutide), marking a significant step in expanding its non-COVID revenue streams. This therapy, obtained from Sciwind Biosciences, positions Pfizer in the rapidly growing weight management drug market in China, diversifying its portfolio. Investors will be closely watching the commercial rollout, pricing, and market share performance, especially given the competitive landscape with established players like Novo Nordisk and Eli Lilly.